- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 05.01. | NASDAQ: Delisting von Bolt Projects Holdings nach Nichterfüllung der Eigenkapitalanforderungen | 1 | Investing.com Deutsch | ||
| 05.01. | Bolt Projects Holdings, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 29.12.25 | Bolt Projects Holdings, Inc. - 8-K, Current Report | - | SEC Filings | ||
| BOLT PROJECTS Aktie jetzt für 0€ handeln | |||||
| 13.11.25 | Bolt Projects Holdings GAAP EPS of -$2.70, revenue of $0.37M | 1 | Seeking Alpha | ||
| 12.11.25 | Bolt Projects Holdings, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 21.10.25 | Bolt Projects announces prelim Q3 results and updates 2025 guidance | 1 | Seeking Alpha | ||
| 17.10.25 | Bolt Projects Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 02.10.25 | Bolt Projects Holdings, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 26.09.25 | Bolt Projects registers 20M shares for potential sale under $20M equity line | 2 | Seeking Alpha | ||
| 26.09.25 | Bolt Projects Holdings, Inc. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 15.09.25 | Bolt Projects Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 29.08.25 | Bolt Projects Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 22.08.25 | Bolt Projects files to sell 913,979 shares of common stock for holders | 1 | Seeking Alpha | ||
| 22.08.25 | Bolt Projects Holdings, Inc. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 15.08.25 | Bolt Projects to raise $4.25M in private placement | 5 | Seeking Alpha | ||
| 15.08.25 | Bolt Projects announces $4.25 million private placement | 1 | Investing.com | ||
| 14.08.25 | Aktie von Bolt Projects bricht nach Kapitalerhöhung mit hohem Abschlag ein | 2 | Investing.com Deutsch | ||
| 14.08.25 | Bolt Projects stock tumbles after discounted share offering | 12 | Investing.com | ||
| 14.08.25 | Pre-market Movers: Sonoma Pharmaceuticals, Bolt Projects, Ibotta, TeraWulf, 180 Life Sciences | 787 | AFX News | BRASILIA (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.50 A.M. ET).In the Green Sonoma Pharmaceuticals, Inc. (SNOA) is up over... ► Artikel lesen | |
| 14.08.25 | Bolt Projects Holdings, Inc. - 8-K, Current Report | - | SEC Filings |
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EDITAS MEDICINE | 1,778 | +2,89 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen | |
| SOL GLOBAL INVESTMENTS | 0,088 | -2,12 % | XFRA NEW INSTRUMENTS AVAILABLE ON 14.01.2026 | The following instruments on XETRA do have their first trading 14.01.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 14.01.2026
Aktien
1 MHY3130D1013 Heidmar Maritime Hldgs.... ► Artikel lesen | |
| TRINITY BIOTECH | 0,697 | 0,00 % | TRINITY BIOTECH PLC - F-1, Registration statement for certain foreign private issuers | ||
| FATE THERAPEUTICS | 1,003 | +6,39 % | Fate Therapeutics, Inc.: Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates | Authorization Received from UK and EU Authorities to Activate ex-US Clinical Trial Sites Supporting the Ongoing Patient Enrollment of FT819, an Off-the-Shelf CD19-targeted CAR T-cell Product Candidate... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 7,090 | -2,74 % | Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis Program | ARCT-032 generally safe and well tolerated
Meaningful trends of clinical activity observed via high resolution CT scans
After only 28 days of treatment with ARCT-032 (10 mg), 4 out of 6 Class... ► Artikel lesen | |
| OVID THERAPEUTICS | 1,300 | 0,00 % | Ovid Therapeutics Inc.: Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer | NEW YORK, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need,... ► Artikel lesen | |
| GENERATION BIO | 5,630 | +0,18 % | XOMA Royalty Corporation Enters into Agreement to Acquire Generation Bio Co. | - Acquisition provides XOMA Royalty with potential milestone and royalty payments under Generation Bio's collaboration with Moderna - - Generation Bio's cell-targeted lipid nanoparticles (ctLNP) delivery... ► Artikel lesen | |
| CABALETTA BIO | 2,190 | 0,00 % | Cabaletta Bio stock rating reiterated by Cantor Fitzgerald on IND clearance | ||
| LONGEVERON | 0,532 | -3,66 % | Longeveron Granted U.S. Patent for Method of Treating Aging-related Frailty in Patients with Inflammaging Using its Proprietary Stem Cell Therapy | The patent relates to methods of administering therapeutically effective amounts of isolated allogeneic mesenchymal stem cells (MSCs) to patients with aging-related frailty with inflammagingNo approved... ► Artikel lesen | |
| VOR BIOPHARMA | 17,590 | 0,00 % | Vor Biopharma: Vor Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Multiple Late-Stage Data Readouts Reinforce Telitacicept's Broad Potential Across Autoimmune DiseasesExpansion of Executive Leadership and Board Strengthens Global Development Capabilities Expected... ► Artikel lesen | |
| QIAGEN | 48,000 | 0,00 % | DZ BANK stuft QIAGEN NV auf 'Kaufen' | FRANKFURT (dpa-AFX Analyser) - Die DZ Bank hat die Einstufung für Qiagen beim fairen Aktienwert von 50 Euro auf "Kaufen" belassen. Der Diagnostikspezialist habe seine Mittelfristziele für Wachstumstreiber... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 324,08 | 0,00 % | Praxis Precision Medicines, Inc. (PRAX) a Strong Buy, Per Wall Street Consensus | ||
| ARCELLX | 72,17 | 0,00 % | Legend Biotech Arcellx rise after FDA draft guidance on multiple myeloma trials | ||
| APOGEE THERAPEUTICS | 82,04 | +1,57 % | Apogee Therapeutics auf Rekordhoch: Aktie erreicht 81,0 USD | ||
| COGENT BIOSCIENCES | 39,900 | +2,47 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Anticipated 2026 Commercial and Clinical Milestones for Bezuclastinib and Precision Therapies Portfolio | New Drug Application (NDA) for NonAdvSM submitted in December 2025, NDA submission for AdvSM on track for 1H 2026NDA submission for GIST on track for April 2026; bezuclastinib has the potential to... ► Artikel lesen |
BOLT PROJECTS HOLDINGS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,583 Euro und damit -27,01 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BOLT PROJECTS HOLDINGS INC finden Sie auf Wallstreet Online.